

# CITATION REPORT

List of articles citing

**When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy**

**DOI: 10.1002/dmrr.2981**

**Diabetes/Metabolism Research and Reviews, 2018, 34, e2981.**

**Source:** <https://exaly.com/paper-pdf/69221920/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018. <i>Obesity Medicine</i> , <b>2019</b> , 14, 100099	2.6	
17	Are SGLT2 inhibitors joining the mainstream therapy for diabetes type2?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2019</b> , 13, 1893-1896	8.9	
16	Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. <i>Journal of Internal Medicine</i> , <b>2019</b> , 286, 16-31	10.8	16
15	Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2020</b> , 36, e3223	7.5	10
14	Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study. <i>Mayo Clinic Proceedings</i> , <b>2020</b> , 95, 101-112	6.4	3
13	Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect $\beta$ cell function in LADA patients: A 1-year pilot study. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2020</b> , 36, e3298	7.5	10
12	Rationale for Timely Insulin Therapy in Type2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 1645-1666	3.6	12
11	Sodium Glucose Cotransporter Inhibitors for the Treatment of Diabetes. 1-30		
10	Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 708372	5.7	2
9	Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea. <i>Diabetes and Metabolism Journal</i> , <b>2021</b> , 45, 502-504	5	
8	Glucose-lowering medication selection in patients with diabetes and acute cerebrovascular accident. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , <b>2020</b> , 19, 94-98	0.9	
7	Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation. <i>Diabetes and Metabolism Journal</i> , <b>2020</b> , 44, 785-801	5	
6	Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion.. <i>Journal of Family Medicine and Primary Care</i> , <b>2021</b> , 10, 4398-4409	1.5	
5	Alternate day add on therapy with dapagliflozin in patients with type 2 diabetes mellitus: potential benefits and concerns.. <i>Expert Review of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	0
4	Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin. <i>Primary Care Diabetes</i> , <b>2022</b> ,	2.4	
3	Scientific and ethical issues in add-on designs for antidiabetic drugs. <b>2022</b> , 78, 1399-1401		
2	Preparing for Colonoscopy in People with Diabetes: A Review with Suggestions for Clinical Practice.		0

- 1 Benefits vs risks: SGLT-2 inhibitors in older adults living with frailty: a retrospective study from a university hospital.

o